Analyst George Hill wrote that he upgraded TDOC “given what we see as a compelling valuation, a deliverable strategy for the BetterHelp business, and a comparable transaction illustrating the road map as a path forward.”

“While BetterHelp has been shrinking, the company has a stabilization and growth plan for the longer term,” Bloomberg reported, quoting Hill. “While this will take some time, we view this as a better business with longer-term growth prospects,” the analyst added, maintaining his $11 target on the stock.

With over a 40% decline during the past 12 months, Teladoc (TDOC) is a Hold-rated stock on Wall Street.

However, soon after its Q4 2025 results in late February, the New York-based Health Tech was the subject of another upgrade as Bank of America upgraded it to Buy from Neutral, also citing the prospects of BetterHelp.

The post Teladoc jumps as Deutsche Bank upgrades on valuation appeared first on Up2info.com.

On Wednesday after the close, the New York-based health tech reported $642.3M in revenue, exceeding the consensus by $6.9M, as its Integrated Care segment generated $409.1M with ~5% YoY growth even as BetterHelp revenue fell ~7% YoY to $233.2M.

However, according to BofA analyst Allen Lutz, BetterHelp’s marketing intensity would decline, and its margins would improve as it transitions from a direct-to-consumer model to insurance coverage, a strategy followed by its rival Talkspace (TALK).

Lutz pointed out that Talkspace’s (TALK) EBITDA margins have improved to 11.5% at the midpoint of the 2026 outlook from (9%) in 2023 as it pivoted to insurance coverage from being a DTC platform.

“Assuming that BetterHelp can transition 50-60% of its revenue to insurance coverage by 2028 would support an enterprise value of $1.2B (at 2.5x revenue), more than TDOC’s entire valuation today before including Integrated Care and Livongo,” Lutz wrote.

He upgraded Teladoc (TDOC) to Buy from Neutral and reaffirmed his $7 price target on the stock.

The post Teladoc upgraded at BofA on BetterHelp prospects appeared first on Up2info.com.

Management View

• CEO Charles Divita described the quarter as a “solid finish to 2025 as well as progress we’ve made across our strategic priorities.” He reported consolidated revenue of $642 million and adjusted EBITDA of $84 million with a 13% margin for the quarter. Net loss per share was $0.14, including amortization of intangible assets and stock-based compensation.

• Divita highlighted Integrated Care revenue of $409 million, a 4.7% increase over the prior year, and noted that acquisitions of Catapult Health and TeleCare contributed to growth. Chronic Care program enrollment reached 1.19 million, and U.S. integrated care membership ended at 101.8 million.

• The CEO emphasized advancements in the U.S. Integrated Care segment, referencing the launch of the “enhanced 24/7 care offering” and ongoing innovations in chronic care programs supported by “new AI-enabled stratification capabilities.” Divita also spotlighted new connected devices, in-home testing, and product pipeline advancements.

• He discussed scaling BetterHelp’s insurance offering, now live in 20 states and Washington D.C., with more than 4,500 credentialed and enrolled providers and “an annualized revenue run rate of over $40 million.” Partnerships were announced with AARP and Walmart, alongside international expansion into France, Germany, the Netherlands, Spain, and Austria.

• Divita outlined investments in AI: “Pulse brings together and unifies our extensive data, provides context, applies intelligence and most importantly, connects AI-driven insights to activation and orchestration in support of patient care.”

• Operational excellence was cited as a key focus, with successful client implementations and ISO 9001 certification for key U.S. integrated care processes.

Outlook

• Teladoc expects full year 2026 consolidated revenue between $2.47 billion and $2.59 billion. Adjusted EBITDA is forecast in the range of $266 million to $308 million, reflecting 2% year-over-year growth at the midpoint. Full year free cash flow is projected at $130 million to $170 million, factoring in BetterHelp’s insurance growth and lower net interest income.

• Stock-based compensation is anticipated to fall below $60 million, down at least $20 million year-over-year. For Q1 2026, consolidated revenue guidance is $598 million to $620 million with adjusted EBITDA between $50 million and $62 million.

• Integrated Care revenue is expected to grow 0.4% to 3.9% over 2025, with a full year adjusted EBITDA margin of 15.1% to 16.1%. U.S. integrated care members are forecast to range from 97 million to 100 million by year end.

• BetterHelp 2026 revenue is guided down 7% to down 0.5% versus 2025, with insurance revenue expected at $75 million to $90 million and an exit annualized revenue run rate above $100 million. Direct-to-consumer revenue is projected down 14% to 9%, while international is expected to see double-digit growth.

Financial Results

• Consolidated revenue for Q4 2025 was $642 million. Adjusted EBITDA for the quarter was $84 million. Net loss per share was $0.14. Full year consolidated revenue was $2.53 billion with adjusted EBITDA of $281 million, an 11.1% margin. Free cash flow for the year was $167 million, and cash and equivalents stood at $781 million.

• Integrated Care segment revenue for Q4 was $409 million. Adjusted EBITDA for Integrated Care was $65 million, with a 16% margin. Chronic Care program enrollment reached 1.19 million, and U.S. integrated care membership finished at 101.8 million.

• BetterHelp Q4 revenue was $233 million. Adjusted EBITDA increased to $18 million, with a margin of 7.9%. Full year BetterHelp revenue was $950 million, down 9% year-over-year. Insurance revenue for the full year was $13 million.

Q&A

• David Roman, Goldman Sachs: Asked about stabilizing the business and the path to consistent revenue growth. CEO Divita responded, “this headwind from subscriptions to visits has continued to be a factor…we do see that moderating and ultimately visit growth being a driver of growth.” He added, “getting BetterHelp turned around and really leaning into the market opportunity in integrated care…is how I would answer that.”

• Richard Close, Canaccord: Queried cross-sell trends in Chronic Care and new product traction. Divita explained that “our ability to manage across conditions is a selling factor…we’re seeing continued good interest in our weight programs and our bundled products.”

• Daniel Grosslight, Citi: Asked about BetterHelp EBITDA ramp. Divita stated, “the level of advertising spend, the most material mover there,” with Vice President Michael Minchak noting that investments to scale insurance impact the first half.

• Sarah James, Cantor: Requested assumptions differentiating the high and low end of 2026 guidance. Divita answered, “guidance ranges in BetterHelp being wider because of the changes we’re making there…in Integrated Care, it’s a little bit tighter.”

• Jailendra Singh, Truist: Sought feedback from 2027 RSP discussions. Divita said, “the macro environment…continues to sort themselves out,” but “we’re having much stronger renewed conversations with health plans…about how our suite of services…can really uniquely help them in the things that are challenging them the most.”

Sentiment Analysis

• Analysts displayed a cautious and probing tone, focusing on organic growth, guidance assumptions, EBITDA trajectory, and the path to stabilization, signaling persistent skepticism about near-term revenue acceleration and margin expansion.

• Management maintained a confident stance, often referencing ongoing progress and new opportunities. Divita used phrases like “we do see that moderating” and “I do believe there’s growth potential in the business,” while also acknowledging existing headwinds. The tone was consistent with prior quarters but slightly more assertive about AI and insurance scaling.

• Compared to the previous quarter, analysts remained persistently focused on BetterHelp’s transition, insurance rollout, and growth inflection, while management increased emphasis on operational rigor, AI innovations, and international opportunities.

Quarter-over-Quarter Comparison

• Guidance language shifted to focus on moderating impacts from the transition to visit-based revenue in Integrated Care and a more optimistic outlook for visit revenue growth.

• The previous quarter highlighted segment-level growth and product innovation but did not provide as much detail on AI deployment and international expansion.

• Analysts in both quarters pressed on organic growth, profitability levers, and insurance scaling. Management’s tone has grown more forward-leaning regarding AI’s impact and insurance’s role in BetterHelp’s trajectory.

• Key metrics revealed Integrated Care revenue growth and a ramp in insurance sessions and coverage, while BetterHelp’s revenue decline rate is expected to moderate.

Risks and Concerns

• Management pointed to ongoing macroeconomic challenges, affordability, rising medical costs, and uncertainty related to government programs such as the Affordable Care Act.

• A $5 million to $7 million tariff headwind is expected in 2026, up from $3 million in 2025, with ongoing monitoring of tariff impacts.

• Potential membership declines in U.S. Integrated Care due to ACA subsidy expirations and Medicaid changes were acknowledged, but management indicated utilization and visit growth could offset revenue impacts.

• Analysts raised concerns about the transition to insurance in BetterHelp, potential margin pressure from reduced ad spend, and the sustainability of insurance-driven growth.

Final Takeaway

Teladoc Health enters 2026 with a focus on advancing AI-driven care models, scaling BetterHelp’s insurance offering, and driving international growth, while maintaining operational rigor and cost controls. The company projects stable consolidated revenue and adjusted EBITDA for the coming year, with strategic priorities centered on innovation in virtual care, managing macro headwinds, and leveraging new partnerships and technology investments to support future growth and performance.

Read the full Earnings Call Transcript

The post Teladoc projects $2.47B–$2.59B revenue in 2026 while advancing AI, insurance, and international growth appeared first on Up2info.com.

The post Earnings Snapshot: Teladoc Health guidance falls short; U.S. revenue down 3%, international up 19% appeared first on Up2info.com.

The post Teladoc Q4 results beat on both lines; 2026 guidance figures include consensus appeared first on Up2info.com.

The post Teladoc Health GAAP EPS of -$0.14 beats by $0.04, revenue of $642.27M beats by $6.94M appeared first on Up2info.com.

The consensus EPS estimate is -$0.22, while revenue is expected to be around $635.33M.

The company had guided 2025 consolidated revenue of $2.510 billion to $2.539 billion and adjusted EBITDA of $270 million to $287 million in the previous quarter. Free cash flow is expected in the range of $170 million to $185 million, it added.

The management projected the Integrated Care segment revenue to rise 2.4% to 3.5%, while it sees BetterHelp revenue narrowing, expecting a decline in the range of 8% to 9.2%.

The company anticipated $12 million to $14 million in 2025 insurance revenue for BetterHelp and updated segment adjusted EBITDA margin guidance to 3.8% to 4.6%.

Teladoc cited persistent headwinds in the U.S. BetterHelp cash-pay segment, coupled with macroeconomic uncertainty and intensifying competition, particularly from insurance-backed providers. It also flagged potential risks due to tariffs, expecting a $3 million hit to adjusted EBITDA.

Seeking Alpha analyst Stephen Ayers expects TDOC’s 2026 revenue guidance to be at least flat, with free cash flow margin meaningfully above ~5%.

“For its BetterHelp segment, users, and revenues need to stabilize, and segment profitability needs to increase. Its Integrated Care unit needs to see monetization improvement. And investors need to be assured that there is a clear path for capital structure and cash durability into 2027,” Ayers said.

The post Teladoc Health Q4 Preview: Here’s what to expect appeared first on Up2info.com.

Teladoc Health (TDOC) shares clocked seven straight sessions of losses on Thursday, as the stock was 3.3% lower at $6.08.

The healthcare technology company lost nearly 16% in the preceding six sessions.

Looking at Seeking Alpha’s Quant Rating, TDOC has a Hold rating with a score of 2.7 out of 5. The company received B+ in the prospect of profitability, while it received D- in the growth factor.

Seeking Alpha analysts are positive and see the stock as a Buy.

Turing to the Wall Street, five analysts have given the stock a Buy or above rating. 22 gave the stock hold recommendation, while none gave Sell rating.

“TDOC’s recent acquisitions, including UpLift and Catapult Health, have not meaningfully offset declining user numbers or driven innovation,” pointed out a Seeking Alpha analysis.

The post Teladoc Health shares tumble for seven consecutive sessions appeared first on Up2info.com.

His remarks came after the court held off a widely anticipated ruling on Trump’s tariffs on Friday in a case closely followed by Costco (COST) and other major companies, which are also involved in the legal fight seeking to benefit from potential refunds.

“It won’t be a problem if we have to do it, but I can tell you that if it happens, which I don’t think it’s going to—it’s just a corporate boondoggle,” Bessent said during an interview with Reuters on Friday.

With nearly $774B of cash on hand as of Thursday, the Treasury can easily cover any refunds, which, according to data from the Customs and Border Protection Agency, could approach $150B based on duties tied to the International Emergency Economic Powers Act. The case challenges Trump’s decision to use IEEPA to impose tariffs on nearly all trading partners of the U.S. in April

However, Bessent said that in his opinion, the longer the ruling gets delayed, the more likely it is that the court will rule in favor of the government.

“We’re not talking about the money all goes out in a day. Probably over weeks, months, may take over a year, right?” he added.

“Costco, who’s suing the U.S. government, are they going to give the money back to their clients?” he argued, noting that companies mostly were not passing tariffs to consumers. There was “very, very little, if any, pass-through,” he said.

According to a Bloomberg analysis, other publicly traded firms suing the Trump administration over tariffs include BorgWarner (BWA), Standex International (SXI), Teladoc Health (TDOC), Moog (MOG.A) (MOG.B), Astronics (ATRO), G-III Apparel Group (GII), Lifetime Brands (LCUT), Plexus (PLXS), Goodyear (GT), Weyco Group (WEYS) and EssilorLuxottica (ESLOF) (ESLOY).

Dole (DOLE) and e.l.f. Cosmetics (ELF) were among the latest to file lawsuits against tariffs this year. Subsidiaries of large corporations, such as Alcoa (AA), Yokohama Rubber (YORUF) (YORUY), Kawasaki Heavy Industries (KWHIY) (KWHIF) have also joined the legal battle.

The post Bessent says U.S. Treasury can easily pay for any tariff refunds appeared first on Up2info.com.

Management View

• CEO Charles Divita stated that “our third quarter consolidated revenue and adjusted EBITDA both came in above the midpoint of our respective guidance ranges,” highlighting the company’s execution and progress on strategic priorities. He emphasized continued innovation in integrated care, noting that “over 100 million people have access to one or more of our services,” and pointed to enhancements in the Prism care delivery platform, which now enables providers to address gaps in care and activate programs based on member eligibility.
• Divita discussed a 4% sequential growth in chronic care program enrollment and introduced AI-enabled clinical intervention pilots for rising and high-risk populations, with plans to bring these innovations to market in 2026. He also highlighted the integration of Catapult, stating it enhances engagement earlier in members’ health journeys and creates cross-sell opportunities for Teladoc’s broader offerings.
• The CEO reported that “visit-based revenues in 2025 now comprise over 50% of our U.S. virtual care revenues compared to approximately 40% in 2023,” and said this mix shift is expected to moderate in impact going forward. For mental health, B2B visits achieved double-digit growth, with BetterHelp generating over $150 million in total revenue, excluding its entry into insurance-covered benefits.
• Divita shared that BetterHelp’s insurance rollout, supported by the UpLift acquisition, is now live in 7 states and D.C., with several more states planned in 2025. He noted that “key metrics at this point are in line with our expectations, including conversion rates, user growth and sessions per user.” The company also acquired Telecare in Australia to expand its international integrated care business.
• The CEO announced that CFO Mala Murthy will be stepping down next month, recognizing her role in shaping Teladoc’s financial strategy.
• CFO Mala Murthy stated, “consolidated revenue of $626 million above the midpoint of our guidance range. Revenue declined 2.2% year-over-year as growth in our Integrated Care segment was offset by a decline at BetterHelp. Adjusted EBITDA of $70 million was at the high end of our guidance range, representing 11.2% margin.” She also cited a net loss per share of $0.28, which included a noncash goodwill impairment charge of $0.07 per share pretax.

Outlook

• Murthy reported that Teladoc now expects 2025 consolidated revenue of $2.510 billion to $2.539 billion and adjusted EBITDA of $270 million to $287 million. Free cash flow is expected in the range of $170 million to $185 million.
• Integrated Care segment revenue is projected to be up 2.4% to 3.5% over 2024, with the midpoint 40 basis points higher than previous guidance, partly due to the Telecare acquisition and strong year-to-date performance. Adjusted EBITDA margin guidance for Integrated Care was raised to 15% to 15.4%.
• The BetterHelp revenue outlook was narrowed to the lower half of the prior range, now expecting a year-over-year decline of 8% to 9.2%. The company anticipates $12 million to $14 million in 2025 insurance revenue for BetterHelp and updated segment adjusted EBITDA margin guidance to 3.8% to 4.6%.

Financial Results

• Teladoc reported consolidated revenue of $626 million and adjusted EBITDA of $70 million. Net loss per share was $0.28, which included a $0.07 per share goodwill impairment charge.
• Integrated Care revenue reached $390 million, up 1.5% year-over-year, while BetterHelp revenue was $236.9 million, including about $4 million from insurance. U.S. Integrated Care membership ended at 102.5 million, up 9% year-over-year, and chronic care enrollment grew to 1.17 million. Integrated Care adjusted EBITDA was $66 million, representing a 17% margin.
• Free cash flow was $68 million for the quarter, with cash and equivalents at $726 million, up $47 million sequentially.

Q&A

• Lisa Gill, JPMorgan, asked about traction for 2026 sales and contracting changes. Divita responded, “I think we’ve made good progress on all of those fronts…the environment is in line with what we’ve spoken about previously, solid overall results in the employer channels really across the solutions and ongoing challenges in the health plan sector.”
• Jamie (for David Roman, Goldman Sachs) inquired about BetterHelp margins amid the insurance transition. Murthy explained, “metrics that we are looking to see in the BetterHelp insurance rollout…are trending in line with what we were expecting. Still early days yet, but we are beginning to see the…operating metrics in line with our expectations.”
• Jessica Tassan, Piper Sandler, asked about customer acquisition cost efficiencies as insurance grows. Murthy noted, “there certainly will be over time, potential efficiencies to be gained on our CAC, on our cost of acquisition.”
• Daniel Grosslight, Citi, asked about Catapult-driven cross-references. Divita described Catapult’s integration as “resonating with the customer base substantially, including with the health plans.”
• Eduardo Ron, Truist, sought updates on insurance sign-up mix and 2027 convert plans. Murthy said it’s too early for detailed conversion metrics but “it is our intent along the way as this scales and seasons, we will provide updates.”
• Additional analyst questions addressed marketing spend cadence, pricing trends for PMPM renewals, payer reimbursement discussions, capacity planning for BetterHelp therapists, and chronic care enrollment opportunities, with management generally indicating stable trends and ongoing investments.

Sentiment Analysis

• Analysts focused on the pace of insurance rollout, profitability, cost discipline, and product adoption, displaying a neutral to slightly cautious tone as they pressed for details on margins, client renewals, and conversion rates.
• Management maintained a confident tone in prepared remarks, emphasizing execution and innovation, but acknowledged market headwinds and early stages for new initiatives. In Q&A, responses were generally measured, with some caution regarding the timing of insurance scaling and chronic care growth. The CEO used phrases like “I think we’ve made good progress” while Murthy was transparent about “still early days yet” on insurance metrics.
• Compared to the previous quarter, both analysts and management maintained a similar tone, with management expressing slightly more confidence in product rollout progress and continued cost discipline, while analysts sustained a focus on execution risks and competitive pressures.

Quarter-over-Quarter Comparison

• Integrated Care revenue growth guidance was raised modestly, while BetterHelp’s outlook was narrowed and reflects a larger decline due to U.S. cash pay headwinds.
• Management highlighted ongoing progress in insurance rollout, now live in 7 states versus a single state soft launch last quarter. Chronic care enrollment returned to sequential growth after a prior period decline.
• The tone of management’s remarks continued to emphasize innovation, operational improvement, and international expansion, with additional detail provided about new pilots, product enhancements, and acquisition contributions (Catapult and Telecare).
• Analysts focused more on the insurance transition impact, cost structure, and selling season outcomes relative to the previous quarter, pressing for specifics on margin and revenue ramp expectations.

Risks and Concerns

• Management cited ongoing headwinds in the U.S. BetterHelp cash pay business, macroeconomic uncertainty, and competitive pressures, especially from competitors offering insurance.
• Tariffs remain a fluid risk, with a $3 million headwind to adjusted EBITDA estimated, and management is evaluating alternative sourcing strategies.
• Analysts expressed concerns about the pace of insurance conversion, client retention, and margin volatility as the product mix shifts.

Final Takeaway

Teladoc Health’s third quarter reflected progress in strategic initiatives, including a broadened insurance rollout for BetterHelp and continued innovation in integrated and chronic care offerings. While Integrated Care performance and cost discipline strengthened guidance, persistent challenges in BetterHelp’s U.S. cash pay segment and macro uncertainty weighed on the outlook. Management remains focused on leveraging recent acquisitions, expanding service offerings, and scaling insurance in additional states, with the expectation that these efforts will drive sustainable growth and improved client value over time.

Read the full Earnings Call Transcript

The post Teladoc sees insurance rollout in 7 states and narrows 2025 guidance while strengthening integrated care appeared first on Up2info.com.